Company Description
Cosmos Health Inc. manufactures, develops, and trades branded nutraceutical products in Greece, the United Kingdom, Croatia, Bulgaria, the United Arab Emirates, Albania, North Macedonia, and Cyprus.
The company provides prescription medications, over-the-counter drugs, medical devices, food supplements, nutraceuticals, cosmetics and other healthcare products under the Sky Premium Life and Mediterranation brand names.
It offers ASTO-CHOL (Pravastatin), Diorium (Omeprazole), HEART-FREE (Clopidogrel), LIPICHOL (Atorvastatin), Miltus (Donepezil), Newzypra (Olanzapine), PNEUMO-KAST (Montelukast), Sahar (Pioglitazone), VIVALCID (Leucovorin), and Diabit-is (Sitagliptin).
In addition, the company offers branded biocides and antiseptic soaps under the C-Sept and C-Scrub brand names; and other pharmaceutical products include Melatonin Spray, used to reduce insomnia and jet lag; Otikon ear drops, which is a Class II medical device in the form of ear drops; and baby foods, such as organic powder milk, pasta with minced meat, whole grain rice cereals, whole grain cereal porridges, and organic rice creams with vanilla milk, as well as pear, carrot and banana purée under the Bio-bebe brand.
It serves wholesalers and retail healthcare providers. The company was founded in 2009 and is headquartered in Thessaloniki, Greece.
| Country | Greece |
| Founded | 2009 |
| IPO Date | Dec 13, 2013 |
| Industry | Medical Distribution |
| Sector | Healthcare |
| Employees | 163 |
| CEO | Grigorios Siokas |
Contact Details
Address: 5 Agiou Georgiou Str, Pilea Thessaloniki, 55438 Greece | |
| Phone | 312 536 3102 |
| Website | cosmoshealthinc.com |
Stock Details
| Ticker Symbol | COSM |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 1474167 |
| CUSIP Number | 221413305 |
| ISIN Number | US2214133058 |
| Employer ID | 27-0611758 |
| SIC Code | 5122 |
Key Executives
| Name | Position |
|---|---|
| Grigorios Siokas | Chairman and Chief Executive Officer |
| Georgios Terzis | Chief Financial Officer |
| Nikolaos Bardakis | Chief Operating Officer |
| Demetrios G. Demetriades | Secretary and Independent Director |
| Prof. Dimitrios Trafalis | Head of Oncology |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 16, 2026 | NT 10-Q | Notification of inability to timely file Form 10-Q or 10-QSB |
| Nov 12, 2026 | SCHEDULE 13G/A | Filing |
| Nov 10, 2026 | 8-K/A | [Amend] Current report |
| Nov 10, 2026 | 8-K | Current Report |
| Oct 30, 2026 | SCHEDULE 13G/A | Filing |
| Oct 29, 2026 | SCHEDULE 13G | Filing |
| Oct 22, 2026 | 8-K | Current Report |
| Oct 16, 2026 | SCHEDULE 13G/A | Filing |
| Oct 9, 2026 | 8-K | Current Report |
| Aug 20, 2026 | 8-K | Current Report |